CytomX Therapeutics (6C1) Financial Statements
CytomX Therapeutics Financial Overview
CytomX Therapeutics's market cap is currently $455.02M. The company's EPS TTM is $-0.45; its P/E ratio is -5.20; CytomX Therapeutics is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $-0.06. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 76.20M | $ 138.10M | $ 101.21M | $ 53.16M | $ 37.31M |
| Gross Profit | $ 76.20M | $ 138.10M | $ 101.21M | $ 53.16M | $ 37.31M |
| Operating Income | $ -22.36M | $ 25.00M | $ -6.48M | $ -101.33M | $ -116.04M |
| EBITDA | $ -15.75M | $ 33.86M | $ 5.50M | $ -96.87M | $ -113.16M |
| Net Income | $ -17.37M | $ 31.87M | $ -569.00K | $ -99.32M | $ -115.87M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 137.05M | $ 100.62M | $ 174.51M | $ 193.65M | $ 305.23M |
| Total Assets | $ 151.57M | $ 120.53M | $ 201.79M | $ 260.89M | $ 339.41M |
| Total Debt | $ 4.24M | $ 9.38M | $ 13.97M | $ 18.06M | $ 21.67M |
| Net Debt | $ -8.43M | $ -28.67M | $ -3.20M | $ -175.59M | $ -183.86M |
| Total Liabilities | $ 52.56M | $ 120.99M | $ 249.24M | $ 346.64M | $ 339.87M |
| Stockholders' Equity | $ 99.01M | $ -456.00K | $ -47.45M | $ -85.75M | $ -459.00K |
| Cash Flow | |||||
| Free Cash Flow | $ -75.81M | $ -86.54M | $ -56.88M | $ -112.53M | $ -120.64M |
| Operating Cash Flow | $ -75.59M | $ -86.23M | $ -56.03M | $ -110.79M | $ -119.03M |
| Investing Cash Flow | $ -59.74M | $ 99.70M | $ -150.67M | $ 98.26M | $ 22.49M |
| Financing Cash Flow | $ 110.45M | $ 7.52M | $ 30.23M | $ 648.00K | $ 110.21M |
Currency in USD